Payment overview · 2025
General Payments
$3,639.21
118 reported records · 27 companies
Healthcare provider profile · identity verified
Jose A Goris, M.D.
Allopathic & Osteopathic Physicians|General Practice · NEW YORK, NY · NPI 1790714962
Verified facts
What the public records show
CMS Open Payments records show Jose A Goris, M.D. received $3,639.21 in general payments during 2025 across 118 reported records.
Intra-Sana Laboratories accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Lumigan by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 342 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 366 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 329 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $472.93 | 13.0% | 9 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $445.97 | 12.2% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $381.32 | 10.5% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $264.14 | 7.3% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $203.47 | 5.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $187.41 | 5.2% | 16 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $164.64 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $156.93 | 4.3% | 8 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $156.00 | 4.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $137.73 | 3.8% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $126.43 | 3.5% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $124.34 | 3.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $98.16 | 2.7% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $90.13 | 2.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $88.46 | 2.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.09 | 2.3% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $84.16 | 2.3% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.25 | 2.3% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $58.28 | 1.6% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $43.70 | 1.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.53 | 1.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.12 | 0.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.55 | 0.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.92 | 0.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.88 | 0.6% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $19.50 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.17 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,639.21 | 118 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $472.93 | 9 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $472.93 | 9 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $472.93 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $381.32 | 13 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $297.63 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $180.12 | 6 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $164.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $156.00 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $148.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $139.00 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $126.43 | 4 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $124.34 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $122.58 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $122.23 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.25 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.29 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $97.17 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $90.13 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $85.09 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.09 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $83.25 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $74.48 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $73.85 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.76 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $59.76 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $59.76 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $58.28 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.90 | 3 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.94 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.94 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $3.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 107 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 44 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 232 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 342 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 366 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 199 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 298 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 98 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 155 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 57 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
199 | 60 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
31 | 14 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
342 | 121 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
366 | 100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
329 | 251 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
155 | 54 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
298 | 72 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
98 | 27 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
107 | 107 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 69 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1512 | 587 |
| Amlodipine Besylate | Amlodipine Besylate | 1053 | 398 |
| Omeprazole | Omeprazole | 1039 | 312 |
| Gabapentin | Gabapentin | 689 | 255 |
| Metformin Hcl | Metformin Hcl | 676 | 270 |
| Losartan Potassium | Losartan Potassium | 568 | 228 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 558 | 224 |
| Diclofenac Sodium | Diclofenac Sodium | 498 | 204 |
| Metoprolol Succinate | Metoprolol Succinate | 491 | 183 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 478 | 173 |
| Pantoprazole Sodium | Pantoprazole Sodium | 454 | 151 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 430 | 165 |
| Tamsulosin Hcl | Tamsulosin Hcl | 406 | 167 |
| Hydrochlorothiazide | Hydrochlorothiazide | 376 | 156 |
| Jardiance | Empagliflozin | 366 | 100 |
| Famotidine | Famotidine | 361 | 111 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 342 | 155 |
| Farxiga | Dapagliflozin Propanediol | 342 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 130 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 329 | 251 |
| Montelukast Sodium | Montelukast Sodium | 308 | 126 |
| Ozempic | Semaglutide | 298 | 72 |
| Lisinopril | Lisinopril | 296 | 107 |
| Fluticasone Propionate | Fluticasone Propionate | 293 | 114 |
| Trazodone Hcl | Trazodone Hcl | 286 | 80 |
| Baclofen | Baclofen | 279 | 108 |
| Clopidogrel | Clopidogrel Bisulfate | 275 | 117 |
| Carvedilol | Carvedilol | 267 | 119 |
| Ezetimibe | Ezetimibe | 256 | 96 |
| Meclizine Hcl | Meclizine Hcl | 236 | 120 |
| Eliquis | Apixaban | 232 | 69 |
| Vascepa | Icosapent Ethyl | 223 | 82 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 223 | 101 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 221 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 205 | 72 |
| Pioglitazone Hcl | Pioglitazone Hcl | 204 | 80 |
| Linzess | Linaclotide | 199 | 60 |
| Januvia | Sitagliptin Phosphate | 186 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 186 | 81 |
| Memantine Hcl | Memantine Hcl | 186 | 75 |
| Torsemide | Torsemide | 175 | 62 |
| Tradjenta | Linagliptin | 175 | 53 |
| Ibandronate Sodium | Ibandronate Sodium | 171 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 53 |
| Simvastatin | Simvastatin | 163 | 70 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 157 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 155 | 54 |
| Ammonium Lactate | Ammonium Lactate | 144 | 54 |
| Mirtazapine | Mirtazapine | 142 | 61 |
| Labetalol Hcl | Labetalol Hcl | 139 | 45 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 136 | 65 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 132 | 53 |
| Metformin Hcl Er | Metformin Hcl | 129 | 64 |
| Trulicity | Dulaglutide | 124 | 36 |
| Furosemide | Furosemide | 121 | 51 |
| Meloxicam | Meloxicam | 121 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 45 |
| Finasteride | Finasteride | 112 | 42 |
| Glimepiride | Glimepiride | 112 | 47 |
| Single Use Swab | Alcohol Antiseptic Pads | 112 | 58 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 107 | 107 |
| Rybelsus | Semaglutide | 98 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 40 |
| Chlorthalidone | Chlorthalidone | 92 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 92 | 35 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 80 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 80 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 78 | 38 |
| Xarelto | Rivaroxaban | 78 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 33 |
| Alendronate Sodium | Alendronate Sodium | 72 | 30 |
| Azelastine Hcl | Azelastine Hcl | 70 | 25 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 69 | 34 |
| Myrbetriq | Mirabegron | 68 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 67 | 32 |
| Sertraline Hcl | Sertraline Hcl | 67 | 24 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 67 | 20 |
| Novolog Flexpen | Insulin Aspart | 65 | 22 |
| Entresto | Sacubitril/Valsartan | 64 | 21 |
| Cromolyn Sodium | Cromolyn Sodium | 63 | 27 |
| Valsartan | Valsartan | 61 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 60 | 24 |
| Donepezil Hcl | Donepezil Hcl | 59 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 18 |
| Nifedipine Er | Nifedipine | 58 | 28 |
| Tresiba Flextouch U-200 | Insulin Degludec | 58 | 23 |
| Trintellix | Vortioxetine Hydrobromide | 57 | 13 |
| Sucralfate | Sucralfate | 56 | 14 |
| Ibuprofen | Ibuprofen | 55 | 31 |
| Latanoprost | Latanoprost | 54 | 22 |
| Memantine Hcl Er | Memantine Hcl | 53 | 18 |
| Enalapril Maleate | Enalapril Maleate | 52 | 23 |
| Celecoxib | Celecoxib | 51 | 23 |
| Hydrocortisone | Hydrocortisone | 51 | 24 |
| Fenofibrate | Fenofibrate | 50 | 20 |
| Clotrimazole | Clotrimazole | 49 | 18 |
| Lansoprazole | Lansoprazole | 49 | 19 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 48 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 47 |
| Levetiracetam | Levetiracetam | 48 | 20 |
| Nitroglycerin | Nitroglycerin | 47 | 19 |
| Spironolactone | Spironolactone | 47 | 19 |
| Atenolol | Atenolol | 46 | 16 |
| Naproxen | Naproxen | 46 | 28 |
| Rivastigmine | Rivastigmine | 46 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 15 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 45 | 25 |
| Fenofibrate | Fenofibrate,micronized | 45 | 19 |
| Procto-Med Hc | Hydrocortisone | 45 | 21 |
| Creon | Lipase/Protease/Amylase | 44 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 14 |
| Azithromycin | Azithromycin | 43 | 41 |
| Doxepin Hcl | Doxepin Hcl | 42 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 42 | 18 |
| Allopurinol | Allopurinol | 41 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 41 | 14 |
| Restasis | Cyclosporine | 41 | 18 |
| Ursodiol | Ursodiol | 41 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 40 | 20 |
| Glipizide | Glipizide | 39 | 16 |
| Propranolol Hcl | Propranolol Hcl | 39 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | 12 |
| Trulance | Plecanatide | 38 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 14 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 36 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | 14 |
| Jentadueto | Linagliptin/Metformin Hcl | 35 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 11 |
| Ramipril | Ramipril | 35 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 33 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 15 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 32 | 18 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 31 | 15 |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Lumigan | Bimatoprost | 31 | 14 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 31 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 30 | suppressed |
| Kerendia | Finerenone | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | 11 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 28 | suppressed |
| Admelog Solostar | Insulin Lispro | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 18 |
| Mometasone Furoate | Mometasone Furoate | 27 | 13 |
| Anastrozole | Anastrozole | 26 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | 12 |
| Folic Acid | Folic Acid | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 26 |
| Diclofenac Sodium Er | Diclofenac Sodium | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 25 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | 19 |
| Mupirocin | Mupirocin | 24 | 15 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Prednisone | Prednisone | 22 | 20 |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 14 |
| Xiidra | Lifitegrast | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Topiramate | Topiramate | 21 | 11 |
| Metronidazole | Metronidazole | 20 | 18 |
| Olanzapine | Olanzapine | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | 12 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Dexilant | Dexlansoprazole | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Ztlido | Lidocaine | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,639.21 · 118 records | Intra-Sana Laboratories | ABRYSVO, ACCRUFER, BREZTRI, Biktarvy, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, FASENRA, GEMTESA, GLYCATE, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, LEQEMBI, LEQVIO, LINZESS, NUCALA, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, RELISTOR, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VIVITROL, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZENPEP | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error